Raymond James & Associates Tg Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 170,160 shares of TGTX stock, worth $5.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

170,160

Previous 125,188 35.92%

Holding current value

$5.47 Million

Previous $2.23 Million 78.72%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$17.21 - $25.28 $773,968 - $1.14 Million	44,972 Added 35.92%	170,160 $3.98 Million
Q2 2024 Jul 19, 2024	SELL	$13.32 - $19.19 $27,026 - $38,936	-2,029 Reduced 1.59%	125,188 $2.23 Million
Q1 2024 Apr 22, 2024	BUY	$13.02 - $21.3 $10,090 - $16,507	775 Added 0.61%	127,217 $1.93 Million
Q4 2023 Jan 16, 2024	SELL	$6.68 - $18.81 $158,636 - $446,699	-23,748 Reduced 15.81%	126,442 $2.16 Million
Q3 2023 Oct 24, 2023	BUY	$8.36 - $26.5 $34,911 - $110,664	4,176 Added 2.86%	150,190 $1.26 Million
Q2 2023 Jul 25, 2023	SELL	$15.48 - $35.0 $353,392 - $799,015	-22,829 Reduced 13.52%	146,014 $3.63 Million
Q1 2023 Apr 14, 2023	SELL	$10.23 - $19.34 $136,775 - $258,575	-13,370 Reduced 7.34%	168,843 $2.54 Million
Q4 2022 Feb 08, 2023	SELL	$5.01 - $11.83 $59,744 - $141,072	-11,925 Reduced 6.14%	182,213 $2.16 Million
Q3 2022 Oct 25, 2022	BUY	$4.57 - $8.4 $79,947 - $146,949	17,494 Added 9.9%	194,138 $1.15 Million
Q2 2022 Aug 12, 2022	BUY	$3.74 - $10.66 $39,831 - $113,529	10,650 Added 6.42%	176,644 $751,000
Q1 2022 May 11, 2022	BUY	$7.81 - $20.45 $53,576 - $140,287	6,860 Added 4.31%	165,994 $1.58 Million
Q4 2021 Feb 08, 2022	SELL	$15.2 - $35.51 $312,679 - $730,476	-20,571 Reduced 11.45%	159,134 $3.02 Million
Q3 2021 Nov 02, 2021	SELL	$21.78 - $40.45 $338,940 - $629,482	-15,562 Reduced 7.97%	179,705 $5.98 Million
Q2 2021 Aug 11, 2021	SELL	$32.5 - $48.96 $316,062 - $476,136	-9,725 Reduced 4.74%	195,267 $7.57 Million
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $76,104 - $99,314	-1,829 Reduced 0.88%	204,992 $9.88 Million
Q4 2020 Feb 12, 2021	SELL	$25.27 - $54.9 $234,353 - $509,142	-9,274 Reduced 4.29%	206,821 $10.8 Million
Q3 2020 Nov 04, 2020	SELL	$18.49 - $27.24 $432,425 - $637,061	-23,387 Reduced 9.77%	216,095 $5.78 Million
Q2 2020 Jul 28, 2020	SELL	$8.9 - $21.84 $303,356 - $744,416	-34,085 Reduced 12.46%	239,482 $4.67 Million
Q1 2020 Apr 21, 2020	SELL	$7.14 - $15.99 $343,184 - $768,559	-48,065 Reduced 14.94%	273,567 $2.69 Million
Q4 2019 Feb 12, 2020	SELL	$5.1 - $11.2 $56,186 - $123,390	-11,017 Reduced 3.31%	321,632 $3.57 Million
Q3 2019 Nov 07, 2019	BUY	$5.38 - $8.99 $105,604 - $176,464	19,629 Added 6.27%	332,649 $1.87 Million
Q2 2019 Aug 06, 2019	SELL	$6.27 - $8.65 $428,974 - $591,807	-68,417 Reduced 17.94%	313,020 $2.71 Million
Q1 2019 May 06, 2019	BUY	$4.02 - $8.04 $206,700 - $413,400	51,418 Added 15.58%	381,437 $3.07 Million
Q4 2018 Feb 11, 2019	BUY	$3.44 - $5.76 $331,564 - $555,177	96,385 Added 41.25%	330,019 $1.35 Million
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $645,562 - $1.75 Million	125,352 Added 115.76%	233,634 $1.31 Million
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $1.47 Million - $1.77 Million	-117,735 Reduced 52.09%	108,282 $1.42 Million
Q1 2018 May 14, 2018	BUY	$8.7 - $16.8 $125,471 - $242,289	14,422 Added 6.82%	226,017 $3.21 Million
Q4 2017 Feb 14, 2018	BUY	$7.35 - $12.3 $899,640 - $1.51 Million	122,400 Added 137.23%	211,595 $1.74 Million
Q3 2017 Nov 13, 2017	BUY	$10.0 - $12.7 $56,870 - $72,224	5,687 Added 6.81%	89,195 $1.06 Million
Q2 2017 Aug 14, 2017	BUY	N/A	83,508	83,508 $839,000

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

87.7M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.67B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Tg Therapeutics, Inc. Transaction History